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ABSTRACT
Treatments currently licensed for Alzheimer’s dementia target cholinergic brain 
systems. In vivo nicotinic receptor binding may provide an early marker of illness and 
treatment suitability. In this pilot, we examined nine patients with amnestic mild 
cognitive impairment (MCI) and ten age and education matched healthy volunteers 
with high resolution SPECT and the nicotinic receptor ligand 123I-5-IA-85380. Uptake 
data were analysed using voxel-based techniques for group comparisons and 
regression analyses with cognitive impairment as covariates. MCI patients had 
discrete reductions in uptake in medial temporal cortex. Correlations with cognitive 
impairment were found in left temporo-parietal areas (Addenbrooke’s Cognitive 
Examination) and bilateral temporo-limbic areas (Reye Auditory Verbal Learning 
Test), and right parahippocampal gyrus (Reye Complex Figure Test) within the 
patient group. In vivo nicotinic receptor binding appears to be sensitive to brain 
changes in MCI. Larger scale explorations of patients undergoing treatment will be 
necessary to evaluate its use in predicting or monitoring treatment response.
KEY WORDS
Alzheimer’s disease; dementia; mild cognitive impairment, amnestic; nicotinic 
acetylcholine receptors; single photon emission tomography
Emma Terrière 3
1. Introduction
In addition to reduced levels of synaptic choline-acetyl transferase and acetylcholine, 
Alzheimer’s dementia (AD) is also associated with changes in muscarinic and 
nicotinic acetyl-cholinergic receptors (nAChRs). Reduced activity of the 42 
nicotinic receptor subtype has been consistently reported (C. Martin-Ruiz, et al., 
2000), both in terms of reduced binding and subunit expression (Burghaus, et al., 
2000, C. M. Martin-Ruiz, et al., 1999, Wevers, et al., 1999). The receptor may be lost
early in the disease process. This indicates the likely importance of 42 nAChRs in 
the pathophysiology of AD and hence their potential as therapeutic targets. 
Demonstration of early changes may lead to advances in early diagnosis and the 
prediction of future decline. 
Mild cognitive impairment (MCI) represents an attempt to define features of the 
dementias in their pre-clinical phases. The original criteria for MCI set out by 
Petersen (Petersen, et al., 2001) require that a person must present i) with a memory 
complaint, ii) show evidence of objective memory decline in relation to age and 
education, iii) demonstrate preservation of other areas of cognitive function and iv) 
activities of daily life and iv) not fulfill criteria for dementia. Recently developed 
research criteria supply a cut-off for prose recall as objective evidence of episodic 
memory impairment (Grundman, et al., 2004).
There is good evidence in vitro and in vivo, using positron emission tomography, that 
nicotinic receptors are reduced in Alzheimer’s disease in proportion with cognitive 
impairment and other pathological changes (Court, et al., 2001, Nordberg, et al., 1997, 
Nordberg, et al., 1995, Nordberg and Winblad, 1986, Perry, et al., 2000, Sabbagh, et 
al., 1998, Sabbagh, et al., 2001). However, initial studies in MCI have been 
inconsistent (Sabbagh, et al., 2006, Sabri, et al., 2008).
Emma Terrière 4
Whilst SPECT with 99mTc-HMPAO- and other blood flow ligands can assist in the 
differential diagnosis of patients with dementia, it is less sensitive than clinical criteria 
in detecting AD (Dougall, et al., 2004). Attention has therefore turned to SPECT with 
radioligands for acetylcholine receptor subtypes. (S)-5-[123I]iodo-3-(2-
azetidinylmethoxy)pyridine (5-IA-85380 or 5-IA) is a nicotine-based radioligand with 
high affinity for the 42-receptor, to a lesser extent to the 7-receptor (Mukhin, et 
al., 2000). High affinity 5-IA binding is seen in thalamus, striatum and temporal 
regions, with some moderate in vitro binding in white matter of cingulate, occipital, 
and temporal areas (Pimlott, et al., 2004). 5-IA SPECT is suitable for the 
quantification of brain nAChRs in healthy human volunteers (Mamede, et al., 2004). 
It is well tolerated and whole body distribution and dosing data have been reported 
(Fujita, et al., 2002, Vaupel, et al., 2003). Age and sex related changes of plasma-
levels and receptor binding have been characterised (Cosgrove, et al., 2007, Mitsis, et 
al., 2008, Mitsis, et al., 2007). 5IA-SPECT abnormalities have been described in first 
studies of AD (O'Brien, et al., 2007, Terrière, et al., 2008). This initial study aims to 
estimate effect sizes of 5-IA uptake changes in mild cognitive impairment to explore 
the possibility of using nAChR binding in differentiating between pre-diagnostic 
groups.
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2. Methods
2.1 Participants
We recruited ten patients with amnestic mild cognitive impairment (MCI) from the 
Edinburgh Neuropsychological Assessment Service for Older People (Lonie, et al., 
2008) and ten healthy elderly control subjects over the age of 59 from amongst friends 
and spouses of patients matched for age, years of education, pre-morbid IQ and sex.. 
All participants gave written informed consent following a protocol approved by the 
Lothian Local Research Ethics Committee (LREC) and the Administration of 
Radioactive Substances Advisory Committee (ARSAC). Subjects were recompensed 
for travelling costs, but received no financial incentive to participate. Prior to study 
entry, all MCI patients completed the Addenbrooke’s Cognitive Examination (ACE), 
a screening measure of global cognitive impairment that includes a score for the 30-
item Mini-Mental State Examination (Mathuranath, et al., 2000), and the Geriatric 
Depression Scale (Yesavage, 1988). They underwent medical and psychiatric 
screening (including blood screen), as well as neuroimaging (x-ray computed 
tomography) to exclude vascular or other brain lesions. One patient did not receive a 
CT scan at assessment, as he did not generate any clinical indication for a scan during 
2 years of 6-monthly follow-up (MMSE: 24 - 28 - 24 – 24 with a pre-morbid IQ of 
120).
MCI patients met the original criteria developed by Petersen and colleagues (Petersen, 
et al., 1999): three had verbal amnestic MCI, two visual, two verbal and visual 
memory impairment, and two had combined verbal amnesia and executive problems. 
We found that using more than one neuropsychological test increased sensitivity to 
detect episodic memory impairment, so we did not use the newer Petersen 
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(Grundman, et al., 2004) criteria that define objective memory impairment by > 1.5 
S.D. deficits on a prose recall test. There is indeed evidence to suggest that the use of 
a single episodic memory measure can result in arriving at an unreliable diagnosis of 
MCI (Brooks, et al., 2008, Lonie, et al., 2008). We thus include a few patients who 
performed only at one standard deviation below control means in some tests. This 
more mildly impaired group (see below) was, if anything, less likely to show brain 
abnormalities.
Subjects who took concomitant psychotropic medication (over the counter 
preparations including gingko biloba and vitamin E were permitted), those with a
history of thyroid disorder, or a history of smoking within the last two years were 
excluded. After also excluding one patient with a SPECT scan that failed quality 
assurance criteria, the imaged group consisted of four males and five females with a 
mean age of 73.9 years (range 65 to 86 years) and a mean MMSE score of 28.9 (range 
28-30). We also recruited a total of ten healthy controls (6 males and 4 females) with 
a mean age of 73.9 years (range 65 to 80 years) and a mean MMSE score was 29.8 
(range 29 to 30). 
2.2 Neuropsychological Testing
A neuropsychological test battery was given to MCI subjects as well as healthy 
controls. It consisted of tests assessing the primary domains of verbal (RAVLT = Rey 
Auditory Verbal Learning Test, (Rey, 1964)) and visual episodic memory (RCF = 
Rey Complex Figure (Rey, 1941)), processing speed (Trail Making Test Part A 
(Reitan, 1985)), and speeded divided attention (Trail Making Test Part B (Reitan, 
1985)). Z-values (Table 2) were computed by subtracting the matched-control group 
mean from individual patient scores and dividing the result by the control group 
standard deviation.
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2.3 Synthesis of 5-IA
5-[
123
I]-A85380 was produced via electrophilic iodo-destannylation of the 
corresponding stannyl precursor, 5-SnBu3-A85380. The radiolabelling was performed 
as described previously (Terrière, et al., 2008). The 5-[
123
I]-A85380 was formulated 
as 150 MBq in 5 ml 0.9 % saline for intravenous injection containing up to 1.5 mg 
ascorbic acid and filtered through a 0.22 μm filter. The 5-[123I]-A85380 was produced 
with an isolated radiochemical yield of 71.6% ± 8.1 (n = 15), a specific activity of 
477.8 GBq/μmol ± 140.7 (n = 14) and had a radiochemical purity of >98 %.
2.4 Scanning procedure
Subjects were treated with oral potassium iodate from the day before to the day after 
the scan date (170mg, 170mg and 85mg respectively). 150MBq (±10%) of 5-[123I]-
A85380 (5-IA) were given by intravenous injection over 30 seconds. To sample early 
tracer uptake affected by regional cerebral blood flow (rCBF), the first five control 
subjects were immediately scanned with a single-slice, high-sensitivity, twelve-
detector head scanner with an in-slice and z-axis resolution of 8.5 mm full width half-
maximum (FWHM) using the intermediate 572-hole collimators (Neuro 900, 
Strichman Medical Equipment Inc., Boston, MA). Data were acquired in axial ‘slices’ 
using spacing of 12mm, each acquired over 120 sec. All participants were scanned 
after four hours for specific binding close to equilibrium of 5-IA, using 7mm slice 
spacing, each slice acquired over 210 seconds.
2.5 Image Analysis
Image data acquisition and analysis: Images were acquired and reconstructed in 3D 
(96x96 matrix with 7mm slice thickness) Neurofocus software version 3.39 
(NeuroPhysics Corporation, Shirley MA, USA). They were checked for artefacts and 
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exported in Analyze 7.5 format (Mayo Foundation, Rochester MN, USA) for VBA 
(128x128 matrix with 5mm slice thickness). Image quality was unacceptable in one 
image due to patient movement (MCI study) and this was excluded from analysis. 
Analysis for regionally specific effects of 5-IA distribution was done with SPM2 
(Wellcome Department of Imaging Neuroscience, University College London, 2003) 
in conjunction with MATLAB version 7.2 (The MathWorks, Inc. Natick MA, USA). 
In order to optimise spatial normalisation, we created a 5-IA template in the following 
manner: The five 5-IA SPECT control images acquired within ten minutes post-
injection (with uptake patterns similar to perfusion scans) were co-registered with 
those acquired four hours post-injection for the same five control subjects, using rigid 
body transformations. Early 5-IA scans were then spatially transformed into MNI-
space using the perfusion template supplied with SPM2. Following this, the 
corresponding five late scans were transformed into MNI space using the parameters 
derived from the individual early scans. The standard 5-IA template was created from 
averaging and 8 mm smoothing the spatially transformed late scans (Terrière, et al., 
2008). SPM2 spatial normalisation was employed (12-parameter affine followed by 
16 iterations of non-linear transformations) to match each subject’s 5-IA image to the 
new 5-IA template (Figure 1).
Statistical analysis: Image intensity was normalised between subjects using 
proportional scaling to a reference region to prevent inter-subject variability masking 
any regional changes. No area of non-specific uptake has yet been identified in 5-IA 
studies. In this study therefore, three different regions were selected as potential 
reference regions for voxel based analysis: 1) the cerebellum, was selected for two 
reasons. It is sufficiently large to be less liable to partial volume effects experienced 
by smaller regions. It is also considered to be without major pathological involvement 
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in Alzheimer’s disease (Elser, et al., 1996, Pickut, et al., 1999, Soonawala, et al., 
2002); 2) the corpus callosum (CC), which has previously been said to exhibit only 
non-specific uptake (Staley, et al., 2005); 3) SPM2’s default: global mean activity 
within the boundaries of 90% maximum activity. The cerebellar binary mask was 
created and used as described previously (Soonawala, et al., 2002), the corpus 
callosum mask by using the segmentation tool in Analyze and the single subject T1 
weighted MRI supplied with SPM. Masks were made smaller than the structure of 
interest to reduce partial volume effects at the edges, i.e. 2.3 cm3 and 3.7 cm3, 
respectively. Each image was scaled appropriately, producing two sets of scaled 
images (to cerebellum and corpus callosum).  All images were finally smoothed with 
a 12-mm FWHM 3D Gaussian filter and a 90% threshold was applied which appeared
to remove most of the regions containing little or no specific 5-IA uptake in both sets 
of scaled data.  
Group differences in 5-IA uptake between MCI and control subjects were assessed 
using t-tests. As it was likely that the MCI group would consist of some patients who 
will go on to develop Alzheimer’s disease and others who will not dement in the 
future, correlation analyses were run within the MCI group with ACE, RAVLT, and 
RCF scores, after removing age as a nuisance variable. As variability of these
cognitive tests was limited amongst controls compared with the patients (see Table 1), 
our power to detect such associations within the control group would have been small,
and so we did not examine these. Data scaled to global brain uptake, cerebellar uptake 
and corpus callosum reference regions were analysed separately. Effects were 
considered if uncorrected p<0.001. If possible, significance levels were also given 
after correction for volume examined and data smoothness (“corrected”).
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3. Results
3.1 Subject data
Table 1 illustrates the demographic and clinical characteristics of the study. 
3.2 Cognitive Testing
Table 2 demonstrates the results of neuropsychological testing. As anticipated, MCI 
patients generally performed worse than controls, in particular in the MMSE and in 
measures of episodic verbal and visuo-spatial memory.
3.3 Group differences in 5IA uptake
After global normalisation, there were significant reductions in medial temporal lobe 
uptake, particularly right (maximum [20, -22, -26], Z=3.40, p<0.001, uncorrected) and 
in right middle frontal gyrus (maximum [50, 26, 26], Z=3.32, p<0.001, uncorrected)
in the MCI patients compared with the controls (Figure 2). Using cerebellar 
normalisation or corpus callosum normalisation, there were no differences between 
MCI patients and controls.
3.4 Regression with cognitive impairment
We examined the relationship between cognitive performance and globally 
normalised 5-IA uptake after removing age-effects (Mitsis, et al., 2008). The 
maximum regression coefficient with Addenbrooke’s Cognitive Examination total 
score (Mathuranath, et al., 2000; see Figure 3a) extended from the left supramarginal 
gyrus [-46, -42, 32] to left superior temporal gyrus and left post-central gyrus (voxel 
maximum: Z=5.16, p<0.019, corrected; cluster-level 5.73 cm3, p<0.001, corrected). A 
second cluster of effects was in the right inferior parietal lobule ([34, -48, 36]: voxel 
maximum: Z=4.09, p<0.001, uncorrected; cluster-level 0.97 cm3, p<0.042, corrected), 
and a third in the posterior lobe of the right cerebellum ([44, -64, -26]: voxel 
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maximum: Z=4.03, p<0.001, uncorrected; cluster-level 3.73 cm3, p<0.001, corrected). 
The maximum regression coefficient with the Rey Auditory Verbal Learning Test, 
total score (Rey, 1964; see Figure 3b) was in left lingual gyrus ([−18 −42 −2]: voxel 
maximum: Z=4.54, p<0.001, uncorrected; cluster-level 1.01 cm3, p<0.04, corrected), 
as well as the right hippocampus ([32, -40, 0]; voxel maximum: Z= 4.22, p<0.001, 
uncorrected; cluster-level 0.92 cm3, p<0.004, uncorrected), and in left claustrum ([-34, 
-4, -10];  Z=3.56, p< 0.001, uncorrected; cluster-level 0.34 cm3, p<0.06, uncorrected). 
The maximum regression coefficient with the Rey Complex Figure delayed recall
(Rey, 1941; see Figure 3c) was found in right parahippocampal gyrus ([34, -30, -14], 
Z=3.58, p<0.001, uncorrected; cluster-level 0.29 cm3, p<0.1, uncorrected).
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4. Discussion
Our primary question was whether mild cognitive impairment is associated with 
abnormal brain uptake of 5-IA. After global normalisation, there was a small medial 
temporal reduction in the MCI group (Figure 2). This would appear plausible, as the 
MCI patients were all classified as amnestic. The extent to which this reduction is 
influenced by (para-)hippocampal atrophy would require a study with co-registration 
to MRI. We felt that an additional within-group correlation with cognitive function 
would be informative, as we expected that within the MCI group some patients were 
likely to be similar to the healthy volunteers while others were more likely to develop
dementia in the near future. Current ACE, RAVLT, or RCF scores are of course not 
validated predictors of outcome, but a first approximation to current cognitive (dys-) 
function. A regression with ACE, RAVLT and RCF yielded significant associations 
within temporal-parietal cortex, emphasising the relevance of cognitive impairment in 
general and verbal/visual episodic memory impairment in particular in this group.
Several novel image analysis steps were introduced with this study. First, a 5-IA 
template was created to optimise spatial normalisation. Second, objectively identified 
cerebellum and corpus callosum regions were used as reference regions to scale data. 
There are recognised limitations of using such reference regions. Preclinical studies in 
nonhuman primates have indicated that there is no grey matter region with only non-
specific binding for 5-IA. The cerebellum demonstrated at least 35% displacement of 
5-IA uptake by nicotine or the nicotinic agonist cystine in nonhuman primates. This 
finding has recently been confirmed in human subjects, where up to 70% of 5-IA 
cerebellar uptake was displaced by nicotine delivered from smoking two consecutive 
cigarettes (Staley, et al., 2005).  A second study of quantification of human nicotinic 
acetylcholine receptors with 5-IA SPECT also concluded that the cerebellum was an 
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inappropriate reference region and the authors indicated that there was no other 
receptor-poor region that is appropriate as a reference region for SPECT (Mamede, et 
al., 2004). Atrophy affecting tissues both with and without nicotinic receptors may 
explain greater group differences after cerebellar normalisation: relative absence of 
cerebellar atrophy in early Alzheimer’s disease and MCI will highlight any relative 
atrophy or perfusion changes in cerebral cortex (Soonawala, et al., 2002). While it is 
likely that there is reduction of cell elements containing nicotinic receptors, this is 
possibly not a specific reduction of such cells. Such partial volume effects are less 
likely if whole brain ratios are used, where all atrophic regions are both in the 
denominator and the numerator. Consequently, the whole brain ratio results were the 
most conservative. Although white matter clearly accumulated the tracer, at least two 
studies suggest that the corpus callosum does not (Ding, et al., 2004, Staley, et al., 
2005). While further work is required to confirm this, using callosum as a reference 
region would greatly simplify quantification of 5-IA uptake. However, as 
demonstrated by our results, its relatively small size and low activity counts could 
introduce significant noise during quantification. As our (most conservative) results 
after whole brain normalisation show significant diagnostic group differences and 
correlations with cognitive impairment can be measured with 5-IA SPECT, this 
imaging modality may be helpful in further exploring brain changes in MCI.
While imaging markers of amyloid accumulation may turn out to be the most 
sensitive method of detecting patients with a high potential to develop Alzheimer’s 
disease, nicotinic binding may prove to be useful in both detecting early changes and 
following functional deterioration and possible interaction with drugs acting on the 
acetylcholine system. Further larger and longitudinal studies will be necessary to 
examine this question.
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Table 1: Mean scores (standard deviations) and p-values for patients 
included in comparisons.  
Diagnostic Group T-Test (p)
Healthy Controls 
(n=10, 6 ♂)†
Mild Cognitive 
Impairment (n=9, 4 
♂)†
Mean SD Mean SD
Age 73.9 6.8 73.9 5.6 0.997
Estimated IQ (NART*) 122.0 1.9 116.9 6.5 0.12
Years of Education 15.4 3.5 14.3 3.7 0.53
Addenbrooke's 
Cognitive Examination
95.9 2.4 91.1 5.2 0.03
Mini-Mental State 
Examination
29.9 0.3 28.9 0.6 0.000
*NART – National Adult Reading Test (Nelson and Willison, 1991), available only 
for 5 controls.
†Chi-square=0.048 (continuity correction), p=0.827
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Table 2: Z-values of neuropsychological test scores for MCI patients –
means and 95%-confidence intervals (note that trails tests are scored as
time to completion, i.e. larger values are more abnormal) - Computed as 
average difference between patient values and control mean divided by 
control standard deviation.
Mean Z-Score 
(Cohen’s d)
95% CI
Addenbrooke's Cognitive Examination -0.94 -1.85 to -0.02
Mini Mental State Examination -1.52 -2.57 to -0.46
Rey Complex Figure Immediate Recall -0.88 -1.62 to -0.14
Rey Complex Figure Delayed Recall -0.81 -1.51 to -0.10
Trails A -0.23 -0.64 to 0.19
Trails B 0.83 -0.20 to 1.86
Auditory Verbal Learning Test (Total) -0.54 -1.10 to 0.02
Auditory Verbal Learning Test (Delayed 
Recall)
-0.31 -0.84 to 0.22
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Figure Legends:
Figure 1: 
5IA Template co-registered with T1-weighted MRI image
Figure 2: 
Group contrast giving relative reductions in 5IA uptake in MCI patients after 
global normalisation (presented at height threshold of T=2.57, p<0.01). Only 
right parahippocampus [22, -22, -26] and right middle frontal gyrus [50, 26, 26] 
achieved criterion of uncorrected voxel-level p<0.001.
Figure 3: 
Correlation of 5IA uptake with A) ACE total score; B) AVLT total score; C) 
RCF delayed score within the MCI group (all presented at height threshold of 
T=5.21, p<0.001)
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Table 2: Z-values of neuropsychological test scores for MCI patients –
means and 95%-confidence intervals (note that trails tests are scored as
time to completion, i.e. larger values are more abnormal) - Computed as 
average difference between patient values and control mean divided by 
control standard deviation.
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